Scientists Take Aim at Impact Factor

A declaration asks the scientific community to put less weight on the metric, widely used to evaluate journals’ prestige.

Written byKate Yandell
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, ELVERT BARNESA declaration asking that the research community pay less attention to impact factor now has 484 signatures, 87 of them from institutions and 397 from individual members of the scientific community. Impact factor is calculated by Thomson Reuters based on academic journals’ citation rates, as a measure of prestige. The document, called the San Francisco Declaration on Research Assessment (DORA), asks that scientists, funding bodies, and others stop using the number as “a surrogate measure of the quality of individual research articles.”

DORA, set into motion at the Annual Meeting of The American Society for Cell Biology (ACSB) in December and spearheaded by the society, argues that, within journals, most citations are likely to come from relatively few papers and so the aggregate impact factors do not reflect an individual paper’s merit. Impact factors also vary by field and don’t differentiate between review papers and original research. And the emphasis encourages editors to enact policies to drive up their impact factors, sometimes artificially, the declaration said.

The declaration also asks that measures of research impact be transparently calculated and openly available for anyone to use. Thomson Reuters currently has not explained its full methodology and its data require permission to use.

“We, the scientific community, are to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies